Dr. Harald Stock
Life Science firm OvaScience has appointed Dr. Harald Stock to its Board of Directors.
Stock, who previously has worked in high-end roles at divisions in Roche and Johnson & Johnson, has served as CEO of the Grünenthal Group, an international research-based pharmaceutical company headquartered in Germany, since 2009.
“The global fertility market is nearly 10 times larger than the U.S. alone, and growing rapidly,” said Dr. Michell Dipp, CEO of OvaScience, adding that “Harald’s expertise and success commercializing products in global healthcare markets will be important to OvaScience as we advance our ex-U.S. strategy.”